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Purpose: This phase II study (S0341) evaluated the efficacy and
tolerability of single-agent erlotinib in unselected chemotherapy-
naive patients with advanced non-small cell lung cancer (NSCLC)
and a performance status (PS) of 2. Exploratory analyses of a
number of biomarkers relating to epidermal growth factor receptor
pathway activation were also performed.
Patients and Methods: Patients with stage IIIB (pleural effusion) or
stage IV NSCLC with a PS of 2 and no prior chemotherapy or
biologic treatment for NSCLC received erlotinib 150 mg daily.
Results: A total of 81 patients entered the study; 76 were assessable.
One complete and 5 partial responses were noted for an overall
response rate of 8% (95% CI 3%–16%). Stable disease (SD) was
seen in 26 patients (34%) resulting in a disease control rate (DCR
CR/PR/SD) of 42%. Progression free and median survival were 2.1
months (95% CI 1.5–3.1) and 5 months (95% CI 3.6–7.2), respec-
tively. One-year survival was 24% (95% CI 15%–34%). Although
treatment was generally well tolerated, grade 3 to 4 toxicity was
reported in 30 patients (40%), including fatigue (16%), rash (9%),
diarrhea (7%), and anorexia (7%). There was one possible treatment
related death (pneumonitis).
Conclusions: In chemotherapy-naive patients with advanced NSCLC
and a PS of 2, single agent erlotinib resulted in an acceptable but
significant level of treatment-related side effects. With an overall DCR
of 42% and median survival of 5 months, results are comparable to
those achieved with chemotherapy in this population. Development of
an epidermal growth factor receptor-directed biomarker selection strat-
egy may optimize use of erlotinib in PS 2 patients.
(J Thorac Oncol. 2008;3: 1026–1031)
The overall prognosis for patients with non-small cell lung(NSCLC) cancer that involves the pleural space or has
spread beyond the thorax is poor. A number of treatment
approaches including the use of frontline platinum based-
chemotherapy with or without bevacizumab have modestly
extended survival and improved quality of life.1–3 The bene-
fits of systemic treatment have been most clearly defined for
patients with a good performance status (PS) (Zubrod 0–1).
The potential benefits and risks of treatment are much less
well characterized in patients with a poor PS. Patients with a
PS of 2 represent a particularly noteworthy dilemma. PS 2
patients constitute at least 35 to 40% of newly diagnosed
patients with advanced NSCLC and have a markedly shorter
survival compared with good PS patients.4 They experience
enhanced adverse effects with systemic therapies and as a
consequence have to a great extent been excluded from clinical
trials. Available information on treatment outcomes in this
population are confined to a limited number of prospective trials
and retrospective subset analyses from several phase III trials.4–7
A number of new molecularly-directed drugs are cur-
rently being evaluated in the treatment of advanced NSCLC.
The epidermal growth factor receptor (EGFR) is the target of
several agents, including the small molecule tyrosine kinase
inhibitors (TKI) gefitinib and erlotinib and the monoclonal
antibody cetuximab. The EGFR TKI’s have demonstrated
value primarily when used as second-line therapy in patients
progressing after platinum-based chemotherapy.8–10 Their
role as primary therapy in patients with advanced NSCLC is
less well defined.11–13 Given their favorable toxicity profile
compared with antineoplastic chemotherapy, they offer a
potentially attractive treatment option in PS 2 patients, where
fear of treatment-related adverse effects is a significant lim-
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itation to the administration of systemic treatment. This phase II
trial was conducted to obtain preliminary information on the
efficacy and tolerability of erlotinib in unselected chemother-
apy-naive patients with advanced NSCLC and a PS of 2. A
number of correlative studies were also incorporated into the
trial in an attempt to gain insights into EGFR biology in this
patient population.
PATIENTS AND METHODS
Eligibility
Patients were required to have histologically or cyto-
logically documented NSCLC, Stage IIIB with malignant
pleural effusion or Stage IV, new or recurrent after previous
surgery and/irradiation. Patients had to have a SWOG PS of
2. All patients were required to have measurable disease, be
18 years of age and have acceptable hepatic, renal, and
hematologic function. Patients with brain metastases, prior
hormonal, chemotherapy or biologic therapy for NSCLC or
active pregnancy were ineligible. The study was approved by
the Institutional Review Board’s of the respective institu-
tions, and all patients gave written informed consent.
Treatment Plan
Patients received erlotinib 150 mg orally daily on a
continuous basis. One cycle of therapy was considered 21
consecutive calendar days. Treatment was continued until
any of the following criteria were met: 1) progression of
disease or symptomatic deterioration; 2) unacceptable toxic-
ity; 3) treatment delay 3 weeks; and 4) patient election to
withdraw from the study.
Dose Modifications
Patients were evaluated at week 2 and then once every
3 weeks to determine toxicities and/or dose modification.
Erlotinib dose level reductions were as follows: starting dose
150 mg/d; first reduction 100 mg/d; and second reduction 50
mg/d. If a third dose level reduction was required or a
treatment delay greater than 3 weeks occurred, the patient
was removed from the study. Patients developing a rash
grade 2 were managed at the discretion of the treating
physician. Rash grade 3 required a dose reduction. Patients
with grade 2 diarrhea occurring despite the optimal use of
loperamide required a dose reduction. Patients developing
grade 2 keratitis required a dose interruption until resolution
or amelioration of findings to grade 1 and then could be
retreated at the discretion of the physician with a dose
reduction. For grade 2 nonhematological toxicity that was
medically concerning (eg, prolonged cardiac, pulmonary, or
neurotoxicity), treatment was held until resolution to grade
1 and then reinstituted with a dose reduction. For other forms
of toxicities grade 3 (with the exception of alopecia),
treatment was held until the toxicity resolved to grade 1 or
less and then treatment was resumed with a dose reduction.
No dose re-escalations were permitted.
Response and Toxicity Criteria
Patients were evaluated for disease response before
every third cycle of treatment. Response was assessed using
RECIST criteria14 and toxicities were assessed using NCI
Common Toxicity Criteria Version 3.0.15
Ancillary Treatment
Patients received supportive care including transfusions
of blood products, antibiotics, and medications with utility in
managing the common adverse effects of erlotinib. These
included topical antibiotics, corticosteroids or short course
prednisone or minocycline for cutaneous toxicities, loperam-
ide for diarrhea, and preservative-free artificial tears and
ophthalmic ointments and ointments for keratitis.
Patient Report Measures
The Medical Conditions Questionnaire developed by
Katz was administered once at study entry for use as a
covariate in analyses.16 The scoring algorithm based on the
Katz system incorporates severity of medical conditions;
higher scores reflect more severe comorbid conditions. A
count of organ systems affected by a medical condition was
also calculated.
Laboratory Correlative Studies
At the time of study entry, patients were offered the
opportunity to participate in a companion protocol S9925
(Lung Master Correlative Science trial) through which blood,
plasma, and tumor tissue for correlative science studies
was collected in consenting patients. Biomarkers relating
to EGFR pathway activation were performed: immunohisto-
chemistry was performed for EGFR protein expression
(DAKO, Glostrup, Denmark # K1494), E-cadherin (DAKO,
Glostrup, Denmark #M3612), and Vimentin (DAKO, Glostrup,
Denmark #M0725). EGFR gene copy number was assessed
using fluorescence in situ hybridization (FISH) using LSI
EGFR SpectrumOrange/CEP 7 SpectrumGreen probes (Vy-
sis, Abbott Laboratories, Abbott Park, IL) as described.17 In
brief, tumors with 4 or more copies of the EGFR gene in
40% of the cells (high polysomy) or tumors with EGFR
gene amplification (gene/chromosome ratio 2, or presence
of gene cluster or 15 gene copies in 10% of the cells)
were considered FISH positive, whereas all others were
considered FISH negative.
Statistical Considerations
Considering that prior studies have shown that erlotinib
results in a relatively low response rate, and that clinical
benefit of erlotinib therapy has largely been defined by
nonprogression, including the category of stable disease
(SD), the primary end point of the trial was overall survival
(OS). The regimen would be considered promising if the true
median survival from registration was 4 months or longer in
this PS 2 patient population, in conjunction with acceptable
toxicity. It would be considered of no further interest if the
true median survival were 2.5 months or shorter. Assuming
exponential survival and 65 patients accrued over 18 months,
with an additional 6 months of follow-up, the study would
have 81% power to rule out the null hypothesis of a 2.5
month median survival at the one-sided 0.05 alpha level
versus an alternative of a 4-month median survival, using a
Brookmeyer Crowley-like test.18 Response rates and toxicity
rates were assessed as secondary endpoints. Sixty-five pa-
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tients would be sufficient to estimate response rates and rates
of specific toxicities to within 12%.
The subset of patients who consented to participate in
S9925, and from whom analyzable specimens were collected
are included in the molecular correlative studies. The results
for FISH score, ECAD index, EGFR index, and Vimentin
index were dichotomized into 2 groups (high versus low)
based on the observed median values. Cox regression models
were fit to investigate the relationships between each biomar-
ker and OS and progression-free survival (PFS). The rela-
tionship between each biomarker and response rate and dis-
ease control rate were explored using logistic regression
methods and exact tests. This analysis was considered ex-
ploratory in nature, with the objective of generating hypoth-
eses for future Phase III studies. Therefore no adjustments for
multiple comparisons were made. Because of the limited sample
size, there would only be sufficient power to detect very strong
relationships. Exploratory analyses also examined the prognostic
value of the extent of baseline comorbidities.
RESULTS
Patient Characteristics
Between September 15, 2004 and October 1, 2005, 81
patients were registered onto the study. Five patients were
ineligible for the following reasons: incorrect timing of pre-
study assessments (2); insufficient documentation of correct
stage (1); prior chemotherapy (1); no measurable disease. (1)
Characteristics of the 76 eligible patients assessable for re-
sponse, survival, and toxicity are displayed in Table 1. Most
patients (87%) had Stage IV disease and the median age was
74 years (range 47–89). Males and females were nearly
evenly divided and approximately one-half of patients (51%)
had an adenocarcinoma pathologic subtype. Eight-nine per-
centage of patients were current or former smokers.
Treatment Received
Median time on treatment was 49 days (range 4–866).
One patient remains on treatment. Forty-four patients (58%)
and 18 patients (24%) discontinued treatment secondary to
progressive disease and toxicities, respectively.
Toxicity
Treatment related toxicity (grade 3) is displayed in
Table 2. Grade 4 toxicities were uncommon. A total of 6
grade 4 events were noted in 5 (7%) patients. They included:
fatigue (3 patients), dyspnea (2 patients) and renal failure (1
patient). One-third of patients had a grade 3 toxicity. The
most common grade 3 toxicities included: fatigue (9 pa-
tients), rash (7 patients), diarrhea (5 patients), and anorexia (5
patients). There was one probable treatment-related death in
a patient who developed pneumonitis.
Response and Survival
Objective response to treatment is displayed in Table 3.
One patient (1%) achieved a complete response and 5 patients
(7%) partial responses. SD was seen in 26 patients for an
overall Disease Control Rate (complete  partial response 
TABLE 2. Toxicity (Grade 3) (N  76)
Adverse Effect
Grade 3
No. of Pts (%)
Grade 4
No. of Pts (%)
Grade 5
No. of Pts (%)
Constitutional
Dehydration 3 (4) 0 0
Fatigue 9 (12) 3 (4) 0
Weight loss 2 (3) 0 0
Gastrointestinal
Anorexia 5 (7) 0 0
Diarrhea 5 (7) 0 0
Nausea 1 (1) 0 0
Vomiting 1 (1) 0 0
Hematologic
Anemia 2 (3) 0 0
Lymphopenia 2 (3) 0 0
Pulmonary
Dyspnea 2 (3) 2 (3) 0
Pneumonitis 0 0 1 (1)
Renal
Renal failure 0 1 (1) 0
Skin
Rash 7 (9) 0 0
Maximum grade
any toxicity
25 (33) 5 (7) 1 (1)
TABLE 3. Treatment Outcome (N  76)
Response No. of Patients %
Overall 6 8 (3–16*)
Complete 1 1
Partial 5 7
Stable 26 34
Progressing disease 28 37
Early death 1 1
Assessment inadequate 10 13
*95% Confidence.
TABLE 1. Patient Characteristics (N  76)
Variable No. of Patients %
Median age, years (range) 74 (47–89) –
Male: Female 36:40 47:53
Cell type
Adenocarcinoma 39 51
Squamous cell 18 24
Large cell 1 1
Other 18 24
Stage
IIIB 10 13
IV 66 87
Smoking history
Current 26 34
Former 42 55
Never 6 8
Missing 2 3
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SD) of 42% (32 patients). Ten patients had inadequate as-
sessments of response and are presumed nonresponders. Rea-
sons for inadequate assessment included: no follow-up as-
sessment performed (7 patients); inconsistent assessment
methods (2 patients); delinquent data (1 patient). Median
follow-up for surviving patients is 21 months (minimum
17/maximum 32 months). Median progression free survival is
2.1 months (95% CI 1.5–3.1 month). Median OS is 5 months
(95% CI 3.6–7.2 months) (Fig. 1). Survival at 1 and 2 years
is 24% (95% CI 15%–34%) and 14% (95% CI 7–23%),
respectively.
Patients with Katz scores of 0 (N  18), 1 (N  14),
and2 (N 42) had median survivals of 4, 6, and 5 months,
respectively. Patients with organ counts (number of organ
systems involved by significant comorbid conditions) of 0
(N 18), 1 (N 22), and2 (N 34) had median survivals
of 4, 5, and 6 months, respectively.
Molecular Correlative Studies
Although sixty-six patients consented to submission of
biologic specimens, assessable specimens were received from
only 38 clinically eligible patients, primarily due to scant
cytologic specimens from fine needle aspiration. Addition-
ally, the number of assessable results obtained varied by
marker (range: 19–37). Exploratory analyses were conducted
evaluating the relationship between the biologic markers and
a number of clinical outcomes including response rate, dis-
ease control rate (complete  partial response  SD), PFS,
and OS. Realizing the small sample size for statistical corre-
lations, no significant relationships were noted with any of
the clinical outcomes and EGFR gene copy by FISH (N 
34), EGFR protein expression (N  37) or E-cadherin ex-
pression (N  35). Vimentin index (N  19) 0 was
associated with an improved PFS (P  0.02). When EGFR
FISH scores were analyzed by a dichotomous grouping into
FISH positive (N  15) versus FISH negative (N  19), all
clinical outcomes were numerically more favorable in the
FISH positive group, but none of these comparisons were
statistically significant. These included disease control rate:
53% versus 32% (P  0.3); PFS: 4 versus 1 month (P 
0.44); and OS: 8 versus 5 months (P  0.84) in the FISH
positive and FISH negative groups, respectively.
DISCUSSION
Patients with a PS of 2 constitute a large proportion of
patients with advanced NSCLC and have a clearly inferior
survival when compared with good PS (0–1) patients. A trial
reported by the Eastern Cooperative Oncology Group more
than 20 years ago illustrates the dramatic impact of PS on
survival and toxicity from treatment.19 Whereas patients with
a PS of 0 and 1 had median survivals of 8.3 and 6 months,
respectively, median survival for PS 2 patients was only 2.3
months. Similarly, toxic deaths were seen in 3% of good PS
patients compared with a toxic death rate of 10% in PS 2
patients. As a consequence of the clinical outcomes from this
and similar trials, participation of PS 2 patients in frontline
advanced stage NSCLC studies has often been restricted,
limiting the body of clinical data available to guide treatment
decisions by practicing oncologists.
To date, our understanding of the value of chemother-
apy in patients with advanced NSCLC and a PS of 2 is
derived primarily from retrospective subset analyses from
therapeutic trials composed predominantly of good PS pa-
tients, and a few recent prospective trials exclusively target-
ing PS 2 patients. An analysis of the small cohort of patients
with a PS of 2 from the ELVIS trial comparing single agent
vinorelbine with best supportive care in patients70 years of
age suggests a benefit for chemotherapy. Median survival
was 6 versus 2 months in the vinorelbine and supportive care
arms, respectively.20 Whether standard platinum-based dou-
blets are superior to single agents is unclear, as no prospec-
tive Phase III trial has been reported to date addressing this
question. A preplanned subset analysis of CALGB 9730
comparing carboplatin/paclitaxel with paclitaxel alone in the
PS 2 subset suggested improved outcome with the combina-
tion, with median survivals of 4.7 and 2.2 months, respec-
tively.21 Conversely, in a trial evaluating platinum/vinca
alkaloid combination therapy versus vinorelbine alone,
Le Chevalier and colleagues noted no survival difference be-
tween single versus combination therapy in the PS 2 cohort.22
In recent years, a number of prospective chemotherapy
trials targeting PS 2 patients with advanced NSCLC have
been completed, including 2 trials conducted in the US by
National Cancer Institute sponsored cooperative groups.23,24
Eastern Cooperative Oncology Group trial E1599, a random-
ized phase II trial, compared 2 platinum-based combination
regimens (carboplatin/paclitaxel and gemcitabine/cisplatin)
and noted median survivals of 6.7 and 6.1 months, respec-
tively.23 The Southwest Oncology Group evaluated a sequen-
tial single agent chemotherapy approach employing vinorel-
bine followed by docetaxel in patients age 70 with PS of 0
to 1 or PS 2 patients any age, S0027.24 Median survivals were
5 months in the PS 2 cohort and 9 months in patients 70 PS
0 to 1.
Although the results reported with chemotherapy in
advanced NSCLC patients with PS 2 would suggest some-
what improved outcomes compared with historical results
with best supportive care alone, the persistently disappointing
0%
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FIGURE 1. OS for 76 eligible patients.
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survival rates and concerns about excessive toxicity with
chemotherapy in this impaired population make a compelling
case for new treatment approaches. The recent availability of
a number of relatively well tolerated new therapeutic agents
directed against molecular targets relevant to NSCLC offers
an attractive therapeutic option. Agents in this category
include those that target the EGFR, expressed in a substantial
proportion of patients with NSCLC.25,26
In the current trial, we demonstrate that single agent
erlotinib resulted in an acceptable but significant level of
treatment-related side effects for a substantial minority of
chemotherapy-naive patients with advanced NSCLC and PS
2, including one probable treatment-related death. The rates
of objective response and overall disease control seem similar
to the experience noted in other trials treating unselected
populations of patients with single agent EGRF-TKI’s. In
addition, the median survival of 5 months is comparable with
that reported in prior trials employing chemotherapy alone in
the PS 2 population.23,24,27 A recently reported randomized
phase II trial comparing erlotinib with the combination of
carboplatin and paclitaxel in PS 2 patients with advanced
NSCLC also noted a similar median survival (6.5 months) in
the erlotinib monotherapy arm.28 Of note, survival was nu-
merically higher (9.7 months) in patients randomized to the
chemotherapy arm in this trial.
The results of our study suggest that erlotinib does not
offer a significant treatment advance over chemotherapy in
unselected PS 2 patients, and either selection of patients by
clinical criteria or an EGFR biomarker-driven strategy could
prove more effective. A number of clinical factors, such as
adenocarcinoma histology, female gender, never-smoking
status, and Asian ancestry, have been identified as predictors
of benefit for EGFR-TKI’s.29,30 In addition, a number of
molecular factors, such as EGFR protein expression assessed
by IHC, EGFR gene copy number determined by FISH, and
activating EGFR mutations in exons 19 and 21, have also
been found to have potential predictive benefit.31–35 In regard
to survival outcomes, most consistent results have been
demonstrated for EGFR gene copy number detected by
FISH.32,36
An important component of the current study was to
perform exploratory correlative science studies. Unfortu-
nately, the small specimen sample size in our study and the
relatively modest yield of biologic specimens (approximately
50% of evaluable patients), limit interpretation of our results.
Regardless, a vimentin index 0 was associated with im-
proved PFS, a finding meriting further discussion. Gene
expression studies in NSCLC cell lines have indicated that
transition from an epithelial to mesenchymal phenotype may
confer insensitivity to erlotinib.37 Vimentin is a classic
marker for mesenchymal expression; preclinical studies pre-
dict reduced sensitivity to EGFR-TKI’s in cells over express-
ing this marker. The counter-intuitive improvement in PFS
noted in our study in patients with higher vimentin expression
may be explained by mere chance alone due to the small
sample size (19 patients), the multiple comparisons made in
this analysis, or other factors not yet clarified in EGFR-
related biology.
A growing body of data suggests that high EGFR gene
copy number as determined by FISH may be a useful
predictive marker in patients receiving EGFR TKI’s. Both
single-arm studies17,38 and phase III trials comparing gefitinib
and erlotinib to placebo32,36 have demonstrated increased
survival in patients with tumors demonstrating high EGFR
gene copy number. In our trial, patients with high tumor EGFR
gene copy number did numerically better in all outcome param-
eters, when compared with patients with low EGFR gene copy
number. For the reasons noted above interpretation of these data
are limited.
Efforts to optimize use of the EGFR-targeted therapies in
patients with advanced NSCLC through biomarker selection
strategies are continuing. An Intergroup trial (N0723) will use a
biomarker validation clinical trial design for EGFR FISH in
second line therapy for patients with advanced NSCLC random-
ized to receive erlotinib versus pemetrexed. In SWOG, efforts to
further define the respective roles of erlotinib and chemotherapy
in PS 2 patients will employ a recently reported serum proteo-
nomic predictor based on matrix-assisted laser desorption ion-
ization mass spectrometry to identify patients likely to benefit
from EGFR-TKI’s.39 Chemonaive advanced NSCLC patients
with PS 2 who test positive by the proteonomic profiler will be
randomized to either erlotinib alone or a combination of inter-
mittent erlotinib plus chemotherapy, testing the concept of phar-
macodynamic separation.40 These studies and other planned
biomarker-driven strategies designed to personalize therapy in
patients with advanced stage NSCLC offer promise for improv-
ing the risk/benefit ratio in the large PS 2 population which is
poorly served by currently available therapies.
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